Now Playing
Opinion|Videos|December 18, 2023
Evolving Front-line Treatment Options for CLL
In this Cancer Network Around the Practice program, Mazie Tsang, MD offers an overview of the current landscape surrounding frontline therapy in CLL.
Advertisement
Episodes in this series
Advertisement
Related to this article
The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.
“Those of us who work with NK cells have no doubt that they are incredibly powerful at killing cancer cells,” said Veronika Bachanova, MD, PhD.
Experts discuss why the convenience of the all-oral decitabine/cedazuridine plus venetoclax regimen does not reduce the need for close monitoring in AML.
Veronika Bachanova, MD, PhD, discussed how the favorable safety profile of CAR natural killer cell therapies may come with trade-offs in persistence and response durability.
Developers have resubmitted the biologics license application for tabelecleucel following feedback from a Type A meeting in April 2026.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer
2
Building out a Radiopharmaceuticals Program in Oncology Care
3
How Emory Became the First Adopter of the Liberty Endovascular Robotic System
4
Iberdomide Combination Doubles PFS vs SOC Therapy in R/R Multiple Myeloma
5